<![CDATA[Managing Safety and Infection Risk With Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma]]>

BCMA-directed bispecific antibodiesNeutral

AI Analysis

Summary

Discussion of safety management strategies and infection risk mitigation for BCMA-directed bispecific antibodies in treating relapsed/refractory multiple myeloma, led by Drs. Dhakal, Mewawalla, and Huff.

Importance:2/10

Sentiment:

0.00

safetyinfection riskbispecific antibodiesmultiple myelomaBCMA-directedrelapsed/refractory

Read the original article

Published by Cancer Network on July 20, 2026 12:05 PM

Read Original